NATR$26.67
Chart
Performance
Key Stats
AI NATR Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldNature's Sunshine Products (NATR) presents a mixed investment profile. It shows moderate financial health and a niche market position. However, its recent performance and valuation metrics suggest a cautious approach is warranted. Technical indicators are predominantly bearish in the short to medium term.
Thematic
Nature's Sunshine operates within the natural health and wellness sector, which has growing consumer interest. However, its competitive positioning and ability to leverage broader health trends like personalized nutrition or preventative care need further assessment.
Fundamental
Nature's Sunshine exhibits stable financial footing with decent profitability, but growth has been inconsistent. Valuation metrics are mixed, with a P/E that is somewhat high for the current growth rate.
Technical
The stock is trading below its key moving averages and shows weak momentum, suggesting potential downside risk or a period of sideways consolidation.
| Factor | Score |
|---|---|
| Natural Health & Wellness Trend | 70 |
| Product Diversification | 60 |
| Distribution Channels | 50 |
| Sustainability & ESG | 40 |
| E-commerce & Digitalization | 50 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 60 |
| Growth | 50 |
| Balance Sheet Health | 85 |
| Cash Flow | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume | 60 |
| Support & Resistance | 60 |
| Moving Averages (Longer Term) | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Attractive Valuation Metrics
The trailing Price-to-Earnings (P/E) ratio of 31.0 (TTM) and 35.2 (2024) suggests a potentially reasonable valuation given the company's historical performance and forward-looking estimates. The Price-to-Sales (P/S) ratio of 0.8 (TTM) is also competitive.
Positive EPS Surprises
The company has demonstrated a history of beating earnings estimates, with positive surprises in multiple recent quarters (e.g., Q2 2025: 51.52%, Q4 2024: 64.29%). This indicates a strong ability to manage expectations and deliver better-than-anticipated results.
Bearish Points (7)
Inconsistent Earnings Performance
The company has experienced significant EPS volatility, with large negative surprises in some quarters (e.g., Q1 2025: -110.0%, Q4 2024: 64.29%, Q3 2024: -72.0%). This suggests unpredictability in earnings delivery.
Recent Margin Compression
The net margin in Q4 2024 was negative (-0.3%), and revenue growth has been inconsistent across recent quarters. This indicates potential challenges in maintaining profitability and driving top-line growth.
Calendar
March 2021
26
Ex-Dividend Date
April 2021
9
Next Dividend Date
August 2025
1
Next Earnings Date
H: $0.19
A: $0.17
L: $0.14
H: 113.90M
A: 113.10M
L: 112.30M
Profile
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company provides general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; immune products; cardiovascular products; and digestive products. It also offers personal care products, including oils and lotions, aloe vera gel, herbal shampoo, herbal skin treatment, toothpaste, and skin cleanser products, as well as weight management products. The company provides its products under the Nature's Sunshine Products and Synergy WorldWide brands directly to customers and to a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.
Seasonals
Price Target
20.00 USD
The 39 analysts offering 1 year price forecasts for NATR have a max estimate of 21.00 and a min estimate of 19.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in oncology liquid biopsy and minimal residual disease (MRD) testing, a key growth area for Natera.
Weight: 90
Primary direct competitor in the organ transplant diagnostics market, offering tests for rejection surveillance, similar to Natera's Prospera.
Weight: 88
Major player in cancer diagnostics (Cologuard, Oncotype DX) and liquid biopsy, with some historical overlap in NIPT via acquisition, making them a broad diagnostics peer.
Weight: 85
Specializes in cancer genomics and minimal residual disease (MRD) testing, directly competing with Natera's Signatera in oncology.